The first α-synuclein immunotherapy used in a clinical PD trial was PRX002, a humanized IgG1 monoclonal antibody that acts against epitopes of the α-synuclein C-terminus (Brundin et al. 2017). The gene discussed is SNCA; the disease is Parkinson disease.